[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630510":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":45,"responsibleParty":61,"collaborators":64,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":26,"enrollmentInfo":78,"targetDuration":26,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":48,"whyStopped":26,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Soonchunhyang University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Protein-enriched PPN","EXPERIMENTAL","Patients assigned to this arm will receive a 4th-generation, protein-enriched peripheral parenteral nutrition (PPN). The intervention will be administered for a total of 6 days, starting from preoperative day 1 (POD -1) to postoperative day 5 (POD 5), excluding the day of surgery (POD 0). The daily infusion volume is dynamically individualized; it is titrated based on the patient's target nutritional requirements and their actual daily oral intake.",[13],"Drug: Protein-enriched peripheral parenteral nutrition (Winuf A+ injection)",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard PPN","ACTIVE_COMPARATOR","Patients assigned to this arm will receive a 3rd-generation, standard peripheral parenteral nutrition (PPN). The administration schedule is identical to the experimental arm (a total of 6 days, excluding POD 0). Similarly, the daily infusion volume is individualized and titrated according to the patient's actual oral caloric intake.",[19],"Drug: Standard peripheral parenteral nutrition (Winuf injection)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Protein-enriched peripheral parenteral nutrition (Winuf A+ injection)","A novel, high-amino acid peripheral parenteral nutrition formulation (Winuf A+ injection; JW Pharmaceutical) designed to provide optimal protein delivery with lower glucose load. Administered intravenously.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Standard peripheral parenteral nutrition (Winuf injection)","A conventional, standard 3-chamber peripheral parenteral nutrition formulation (Winuf injection; JW Pharmaceutical). Administered intravenously.",[15],[32],{"name":33,"affiliation":5,"role":34},"Geum Jong Song, MD, PhD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Jong Hyuk Yun, MD, PhD","CONTACT","+82-10-3328-4380","109206@schmc.ac.kr",{"name":42,"role":38,"phone":43,"phoneExt":26,"email":44},"Hyun Seob Shin","+82-10-7687-3350","124909@schmc.ac.kr",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":26,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Soonchunhyang University Cheonan Hospital","RECRUITING","Cheonan","Chungcheongnam-do","31151","South Korea",{"type":54,"coordinates":55},"Point",[56,57],127.1522,36.8065,{"lat":57,"lon":56},[60],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},{"type":34,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Geum Jong Song","Associate Professor of gastrointestinal surgery",[65],{"name":66,"class":67},"JW Pharmaceutical","INDUSTRY","100630510","phase-3-progain-trial-in-gastric-cancer-surgery-100630510",false,"NCT07488611","PROGAIN Trial in Gastric Cancer Surgery","The PROGAIN Trial : A Randomized Study of Protein-enriched Parenteral Nutrition on Nitrogen Balance and Recovery in Perioperative Gastric Cancer Surgery","PROGAIN","Inclusion Criteria:\n\n* Adults aged 19 years or older scheduled to undergo gastric cancer surgery. - Patients who have provided written informed consent to participate in this study.\n\nExclusion Criteria:\n\n* Patients with uncontrolled severe systemic diseases (e.g., decompensated diabetes, cerebrovascular event within the last 6 months, sepsis, heart failure).\n* Patients who have received intravenous parenteral nutrition within 7 days prior to randomization.\n* Patients with severe metabolic abnormalities confirmed by preoperative laboratory tests, including but not limited to:\n\n  * Triglyceride \\> 400 mg\u002FdL\n  * AST or ALT \\> 3 x Upper Limit of Normal (ULN)\n  * Total Bilirubin \\> 3 x ULN\n  * Serum Creatinine \\> 2 x ULN\n  * HbA1c \\> 9.0%\n  * Potassium \\\u003C 3.0 mEq\u002FL or \\> 6.0 mEq\u002FL\n  * Calcium \\> 12.5 mg\u002FdL\n  * Sodium \\> 155 mmol\u002FL\n  * Magnesium \\> 3.0 mg\u002FdL\n* Patients deemed inappropriate for participation in this clinical trial by the investigator.","ALL","19 Years",{"count":79,"type":80},110,"ESTIMATED","INTERVENTIONAL",[83],"PHASE3","This randomized study will evaluate whether protein-enriched parenteral nutrition improves early postoperative recovery in patients undergoing gastrectomy for gastric cancer. Participants will be assigned to receive either protein-enriched parenteral nutrition or standard parenteral nutrition during the perioperative period. The primary outcome is nitrogen balance on postoperative day 5. Secondary outcomes include postoperative complications, recovery of oral intake, and short-term changes in nutritional status and body composition.",[86],"Stomach (Gastric) Cancer",[88,89,90,91,92,93,94],"Parenteral Nutrition","Gastrectomy","Nitrogen Balance","Protein enriched","Perioperative nutrition","Enhanced Recovery After Surgery","Stomach Neoplasms","2026-05-16",{"date":97,"type":98},"2026-05-19","ACTUAL",{"date":100,"type":98},"2026-02-13",{"date":102,"type":80},"2028-03",{"name":5,"class":6},1]